Research Matters

Click here to view previous editions of Research Matters and Research News and Updates.




Latest News

Research Newsletter
January 20, 2015  

NIH Change to annual progress reports received on/after 10/1/14

National Institutes of Health (NIH) annual progress reports received on or after October 1, 2014 must include a section to describe how individual development plans (IDPs) are used to identify and promote the career goals of graduate students and postdoctoral researchers associated with the award.

See more at: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-14-113.html.

 
Skin Diseases Research Center (SDRC)

The Skin Diseases Research Center is funded by a grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. The goal of the Center is to foster translational and basic research in cutaneous biology and skin diseases. The SDRC sponsors innovative research through its Pilot and Feasibility (P&F) Program and plans to support three new P&F projects for funding for one year with an annual budget of $25,000 (direct costs). Projects are supported with the understanding that the PI will subsequently apply for NIH or equivalent funding using preliminary data acquired during the P&F project period.

Application Deadline: Feb. 27, 2015

For more information visit the CTSC pilot programs webpage.

 
NIH Center for Accelerated Innovation at Cleveland Clinic (NCAI-CC)

The NIH Center for Accelerated Innovation at Cleveland Clinic (NCAI-CC) Announces the Request for Applications (RFA) for the third funding cycle.

Funding is available for promising emerging technologies directed towards diagnosis, treatment or management of cardiovascular, pulmonary, blood or sleep-related disorders. NCAI-CC is seeking projects such as therapeutics (e.g. drugs, biologics), preventatives, diagnostics, devices, tools, etc., in order to facilitate their translation to commercialized products that improve patient care and enhance health. The NCAI-CC will provide funding and project assistance to advance the development of high priority early-stage technologies within the mission areas of the NHLBI (cardiovascular, lung, blood and sleep disorders). Expert assistance will be provided in areas required for early technology development, including commercial opportunity assessment, intellectual property, clinical and regulatory, reimbursement, business, legal and project management.

Eligibility: Investigators from the Cleveland Clinic, Case Western Reserve University, The Ohio State University,Cincinnati Children’s Hospital, and University of Cincinnati

Letter of Intent Deadline: February 10, 2015

For more information visit the NCAI-CC website.

 

Foundation Fighting Blindness and Harrington Discovery Institute

Foundation Fighting Blindness and Harrington Discovery Institute have partnered to form, the The National Center for Excellence in Fighting Blindness, a Gund-Harrington initiative. This initiative is focused on accelerating the translation of research findings in inherited retinal degenerative diseases (IRD) with the ultimate goal of developing new therapies to improve and/or restore vision.

• This Initiative seeks to award Gund-Harrington Scholar Awards that recognize innovators throughout the USA whose research has the potential to advance standards of care.
• There will be an average of three awards per year, which will be restricted to researchers working at institutions within the USA. Applications from outside the USA are not accepted.
• The Gund-Harrington Scholar Award provides funding for translational drug development and cell therapy along with non-financial project support to help bridge the gap between laboratory-based research and the clinic.
• Funding up to a total of $900,000 over three years and non-financial support will be provided by the The National Center for Excellence in Fighting Blindness. The non-financial support, provided by a team of pharmaceutical experts, will include project management and experienced industry advice in all aspects of drug development, encompassing chemistry, formulation, toxicology, regulatory, intellectual property and business development.
• Awards will be made to physician-scientists, or scientists with a research team that includes significant involvement of a physician with clinical expertise in the IRD.
• Selected projects must demonstrate a reasonable expectation that they can develop a lead product with strong potential for clinical and commercial application by the end of the three year funding period.
Multi-disciplinary investigators outside the field of retinal disease are particularly encouraged to apply.

Applicants interested in the Gund-Harrington Scholar Awards must apply through Foundation Fighting Blindness.

For more information about Foundation Fighting Blindness visit the Fighting Blindness website.

 
Did You Know?

Grant proposals are due in the Office of Research Administration (or Office of Grants & Contracts in SOM) at least 5 working days before the sponsor’s deadline. This allows time for an institutional review and correction of errors or omissions. As soon as you decide to submit a grant, contact your designated ORA or OGC specialist to let him/her know to expect your proposal. All funding proposals are now submitted on-line through the Sparta system.

Office of Research Administration: https://research.case.edu/index.cfm

Office of Grants & Contracts in SOM: http://casemed.case.edu/grantscontracts/

Sparta System: https://sparta.case.edu/.

 

If you have news or information that you wish to have included in this update, please send it via e-mail to Tracy Wilson-Holden at tracy.wilson-holden@case.edu no later than 5 pm on the Monday of the week that the update is to be distributed. If you know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe to Case Research News, email your request to Tora Williams at tora.williams@case.edu.

Please note: At the time of this transmission, all links functioned. However, Case Research News cannot guarantee that the information will not move or be deleted.